U lcerative colitis (UC) is a chronic disease characterized by inflammation of the colon mucosal layer. The precise etiology of UC is unclear, with interaction of genetic, environmental, and microbiological factors likely playing a role. 1 Dysbiosis in the gastrointestinal tract is thought to be a contributing factor in the development of UC. However, treatment aimed at alteration of the microbiota in UC, such as probiotics and antibiotics, has limited clinical success. 2, 3 Over the last several years, fecal microbiota transplantation (FMT) has been successfully used as a treatment for recurrent Clostridium difficile infection (CDI). 4 Given the potential role of the microbiome in inflammatory bowel disease (IBD), there has been much interest in FMT for IBD. 5 Initial case reports and non-controlled case series of FMT in IBD were promising. A meta-analysis of 119 patients with IBD who received FMT (predominantly for CDI) found that 45% (54 of 119) of patients achieved clinical remission of their IBD during follow-up. 6 Delivery of FMT in these cases was quite heterogeneous, including a variety of delivery modalities and dosing regimens. Three other meta-analyses have since been published, but are limited by heavy reliance on observational data and heterogeneous inclusion criteria. [7] [8] [9] Two randomized controlled trials (RCTs) for FMT in UC have been published since the most recent meta-analysis. 10, 11 Furthermore, no meta-analysis to date has focused on randomized trials or examined endoscopic healing from FMT, an outcome which is felt to be a key endpoint of clinical trials in UC given the long-term outcomes associated with it. 12 To update and improve on the previous systematic reviews, we conducted a systematic review and meta-analysis to evaluate the efficacy and safety of FMT in UC using only high-quality evidence. transplantation in UC. We identified sources from the MEDLINE, Embase, and PubMed databases from the years 1950 to February 2017. There were no language restrictions. Keywords used were {FMT or ([faecal or fecal or feces or faeces or stool] and [transplant* or microbiota or transfusion or implant* or instillation or donor* or enema or reconstitution or infusion* or transfer*]) or bacteriotherapy} and (UC or ulcerative colitis). Both free-text words and subject headings were searched. Variations of root words were searched alone or in combination. High sensitivity filter was used to limit studies to RCTs. The reference lists of any studies meeting inclusion criteria were reviewed manually to identify additional relevant publications. We adhered to PRIS-MA (preferred reporting items for systematic reviews and metaanalyses) recommendations where possible. 13 
Inclusion/Exclusion Criteria
For inclusion in the meta-analysis, studies were required to meet the following criteria: (1) prospective randomized controlled design; (2) enrolled adult subjects with endoscopically and clinically active UC based on clinical assessment scores commonly used for UC; (3) fecal transplantation offered in the interventional arm; and (4) control group receives a placebo consisting of only the FMT excipient (no microbiota) or an autologous FMT. Patients receiving FMT through different modalities (i.e., colonoscopy, enteric tube, or enemas) were all permitted, as were studies that used either single or pooled donor FMT. Where studies did not provide sufficient information, authors were contacted to obtain additional data.
Outcomes of Interest
The primary outcome was short-term combined clinical remission with endoscopic remission or response, assessed after 6 to 12 weeks of therapy. Secondary outcomes included clinical remission, endoscopic remission, and serious adverse events during the intervention period. Adverse events were considered serious if they were infections requiring treatment, hospitalization, surgery, malignancy or death, and occurred during the interventional period. Table 1 reports inclusion criteria and definitions of these outcomes for each study included in the metaanalysis.
Data Extraction and Quality Assessment
Study selection and data extraction was carried out independently by 4 investigators (P.M., Y.Y., N.N. and Z.K.) with discrepancies resolved by consensus in consultation with the senior authors (J.-F.C., C.P. and W.R.). Risk of bias tables were used to assess the quality of randomized studies, as recommended by the Cochrane Collaboration. 13 The risk of bias is assessed in 7 different domains using this tool, including sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective outcome reporting, and other sources of bias. This was done independently by N.N., Y.Y., and P.M., and differences were resolved by discussion. The overall bias for a study is determined to be low if the risk of bias is low in all domains, high if the risk of bias is high in at least one domain, or unclear if the risk of bias is unclear in at least one domain (with no domains having a high risk of bias). We subsequently used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system to determine the overall quality of evidence. GRADE assesses the overall quality of the evidence within many domains, including design, consistency, precision, directness, and publication bias, to determine if further research would lead to changes in the estimate 
Statistical Analysis
Meta-analyses were conducted by combining individual study data into a pooled risk ratio (RR) using a random-effects model. Intention-to-treat data were extracted from all studies. We tested for heterogeneity using the x 2 test and the I 2 test. The x 2 test suggests heterogeneity between studies when the P-value is less than 0.15. The I 2 test describes the percentage of variability in effect estimates that is due to heterogeneity rather than chance, wherein an I 2 test greater than 50% suggests substantial heterogeneity. A random-effects model was used because this provides a more conservative estimate than a fixed effects model when heterogeneity is present. For assessment of publication bias, we planned to perform funnel plots and calculated Egger's regression intercept for studies that reported our primary outcome, provided we identified at least 10 trials. 15 Analyses were performed with 
RESULTS

Search Results
The literature search identified 714 citations, of which 118 were removed due to duplicates. Additionally, 586 were excluded on review of the title and abstracts (Fig. 1) . A further 6 studies were excluded after careful review of the full text; 5 were cohort studies [14] [15] [16] [17] [18] and 1 was a pediatric RCT. 19 Overall, 4 studies (including 1 abstract) with 277 participants were eligible for meta-analysis. 10, 11, 20, 21 
Characteristics of Included Studies
Characteristics of studies included are outlined in Tables 1  and 2 . All 4 studies were prospective RCTs. 10, 11, 20, 21 One study administered FMT through the upper gastrointestinal tract (through nasoduodenal infusion) 21 and the other studies used the lower gastrointestinal tract for administration. 11, 20, 21 Two studies used low frequency of administration (2-3 doses total) 11,21 and 2 studies used higher frequency of administration (6-41 doses total). 10, 20 Two studies used single donor for FMT 20, 21 and 2 studies used pooled donors for FMT preparation. 10, 11 One study ensured all FMT samples were anaerobically prepared. 11 Duration of the studies was between 7 and 12 weeks. All 4 studies reported on all the outcomes of interest. These 4 studies included 140 participants who received donor FMT and 137 subjects received placebo or autologous FMT.
Combined Clincial Remission and Endoscopic Remission/Response
The pooled RR for combined clinical remission with endoscopic remission or response not being achieved in the FMT arm compared with placebo was 0.8 (95% confidence interval [CI]: 0.71-0.89) (P , 0.0001) with an I 2 ¼ 0% and (Fig. 2) . The pooled rate for achieving the combined outcome in these studies is 27.9% for those receiving donor FMT and 9.5% for those receiving the control interventions, for a number needed to treat of 5 (95% CI: 4-10).
Clinical Remission
Significantly more patients receiving donor FMT achieved clinical remission compared with those receiving control interventions, with a pooled RR of not achieving remission was 0.76 (95% CI: 0.62-0.93) (P ¼ 0.01) with an I 2 ¼ 31% and (Fig. 3) . The heterogeneity was driven by the trial that delivered FMT by the nasoduodenal route, 21 and when this was excluded, the RR was 0.70 (95% CI: 0.58-0.85) with no significant heterogeneity (I 2 ¼ 0% and
The pooled rate of clinical remission in all 4 trials was 42.1% in the group receiving donor FMT and 22.6% in those receiving control interventions with an number needed to treat equal to 5 (95% CI: 3-17).
Endoscopic Remission
All studies required the presence of endoscopic inflammation at baseline and assessed for endoscopic improvement at the (Fig.  4) . The pooled rate of endoscopic remission for patients who received donor FMT was 26.4% compared with 10.2% for patients in the control arms.
Serious Adverse Events
Figure 5 demonstrates no significant difference between patients receiving donor FMT compared with control patients with regards to serious adverse events. The pooled RR among the randomized studies was 1.40 (95% CI: 0.55-3.58 [P ¼ 0.49]) with no statistically significant heterogeneity (I 2 ¼ 0% and
The pooled rate of serious adverse events in patients receiving FMT was 7.1% and 5.1% for those in the control group. Two of the patients who received FMT required colectomy, one for worsening of underlying colitis 10 and one for development of C. difficile-associated colitis. 11 There were no mortalities reported in any of the studies.
Quality Assessment and Publication Bias
Risk of bias tables are provided in Appendix 1, Supplemental Digital Content 1, http://links.lww.com/IBD/B615. Table 3 provides a summary of the risk of bias tables. According to the GRADE system for assessing quality, evidence from RCTs begins with a "high" rating. We downgraded the overall rating to low, mainly due to imprecision of treatment effect and because of heterogeneity in methodology of administering the FMT between studies. Details are available in Appendix 2, Supplemental Digital Content 1, http://links.lww.com/IBD/B615. There were too few studies to statistically assess for publication bias. Sensitivity analyses were performed for the primary outcome of combined clinical remission and endoscopic remission/response by removing the study with the largest treatment effect 11 and by removing the study with the largest number of participants, 10 and the significant treatment effect seen with FMT compared with placebo persisted.
DISCUSSION
Fecal microbiota transplantation seems beneficial and safe for treatment of active UC based on the results of this metaanalysis. There remain many questions to be addressed before it can be recommended as routine standard of care.
From a safety perspective, currently there is no long-term safety data for FMT in UC, although the reported long-term experience of FMT for patients with recurrent CDI seems reassuring. 22 However, there are theoretical concerns about conferring microbiome-associated diseases, such as autoimmune conditions, in FMT recipients. Ongoing prospective studies, including a recently funded American Gastroenterological Association (AGA) national FMT registry that aims to prospectively monitor 4000 patients for up to 10 years post-FMT, will help determine the short-term and long-term safety profile of FMT (Clinicaltrials.gov NCT02403622). 23 Rigorous donor screening protocols were used for these studies and would need to be used if FMT were to become acceptable for clinical practice. FMT referral centers with training in FMT, which has been recommended at a European consensus conference, may be helpful in enhancing best practices in safety for FMT. 24 Additionally, the emergence of stool banks with robust screening of universal donors may help facilitate access to safe stool. [25] [26] [27] There is also uncertainty about the most effective delivery modality of FMT. The study from the Netherlands evaluated FMT administered through nasoduodenal tubes and did not find a statistically significant improvement for outcomes such as clinical and endoscopic remission, although it may have been underpowered. 21 Additionally, both studies from Australia used colonoscopy for "induction dose," presumably to guarantee the administration of microbiota in the proximal colon, followed by enemas for maintenance therapy at different intervals. It is unclear if an initial colonoscopic administration is required given the use of enema only in the Canadian study. The use of colonoscopy to deliver FMT may help deliver a larger quantity of stool for induction than retention enemas; however, retention enemas are less expensive and safer to administer. FMT administered by means of oral capsules have been demonstrated to be efficacious for CDI and with a similar engraftment profile as colonoscopy but whether they can be used for UC remains unclear. 28, 29 Overall, no studies of UC have compared the various FMT routes of administration, although an ongoing study (Clinicaltrials.gov NCT03006809) aims to add evidence to this unexplored research area.
Although the concept of adjunct interventions, such as bowel lavage or pretreatment antibiotics, to decrease the bacterial burden and enable healthy microbial engraftment in the host has been speculated upon, there is a paucity of data. In terms of bowel preparation, one study 21 intentionally used bowel lavage before administration of FMT by the upper gastrointestinal tract and results from 2 studies 10,11 may have been confounded by bowel preparation before colonoscopic administration of FMT. Overall, there are conflicting results on the impact of bowel lavage on a host's microbiome and it requires further examination, although positive results from an enema-based study suggests it may not be necessary. 17, [30] [31] [32] Antibiotics are routinely administered before FMT when treating CDI. 33 However, none of the RCTs in this meta-analysis had antibiotic pretreatment as part of their methods. At this time, it is unclear if there is benefit to pretreatment with antibiotics before FMT; however, an ongoing study may clarify this (Clinicaltrials.gov NCT02606032).
The preparation of FMT material may have an impact on the microbiota. Specifically, data suggest oxygen exposure during fecal homogenization alters the composition of living fecal microbiota. 34 Interestingly, the study with the largest treatment benefit used anaerobic techniques for FMT preparation. Additionally, the ideal dosage (grams of stool) for both the induction and the maintenance doses remains uncertain. The fecal dosage was variable across the RCTs, and although there are some dose finding studies in CDI, 35 none have been conducted in UC. In addition to dosage, the frequency of administration also remains ambiguous, as the largest treatment effects were demonstrated in one study with very frequent administration (baseline colonoscopy infusion followed by 5 enemas weekly) 10 and another study with very low treatment burden (baseline colonoscopy infusion and 2 enemas at day 7). 11 Sustainability of FMT treatment effect also is unclear, as 2 studies measured their primary endpoint 6 weeks 11 and 9 weeks 21 after the last FMT treatment, respectively, and the other 2 measured outcomes just after the last administration. 10, 20 The most significant uncertainly in the role of FMT in UC is the impact of the donor. Among a 1999 patient cohort, the selection of donor did not seem to be important for the successful treatment of CDI. 36 The donor; however, seems to impact treatment outcomes when using FMT for UC. This was most evident in study by Moayyedi et al, where most treatment successes were driven by a single donor, "donor B." In this study, enrichment with Lachnospiraceae and Ruminococcus were notable in the stool of donor B and may be associated with treatment success. 20 Other studies have identified other bacterial targets. Rossen et al 21 reported that patients with UC have a lower prevalence of Clostridium clusters IV, XIVa, and XVIII at baseline. Vermeire et al 37 suggested that FMT responders were more likely to acquire the following phylotypes from donors: Roseburia, Oscillibacter, unclassified Lachnospiraceae, and unclassified Ruminococcaceae. Paramsothy et al reported that several microbial taxa were associated with remission, including Barnesiella spp., Parabacteroides spp., Clostridium cluster IV and XVIII, Blautia spp., Dorea spp., and Ruminococcus spp. They also found that Fusobacterium spp. and Sutterella spp. were frequently associated with no remission. 10 Furthermore, it is possible that undetected alterations in the virome and fungome are occurring in responders to treatment. 38, 39 The bacterial, viral, or fungal profile necessary for successful treatment in UC is unclear and may require a "personalized microbial medicine" to identify the ideal patient with UC who will respond to microbial therapies. Overall, further work is required to determine whether deficiencies within the microbiota can be identified in certain patients with UC that would predict successful treatment with FMT.
This meta-analysis demonstrates that short-term use of FMT is beneficial for improvement in clinical symptoms and endoscopic healing of patients with UC. Despite this benefit, there are still unanswered questions that require further research. No controlled studies have yet reported outcomes of maintenance treatment with FMT. Additionally, questions remain regarding donor selection, identification of patients most likely to respond, ideal dosing regimen, and mode of delivery. Cost-effectiveness and need for long-term ongoing treatment is also unclear. Further RCTs and long-term observational registries to capture the safety profile are needed to help clarify some of these uncertainties. Until there is further clarification on some of these questions, FMT for UC should remain confined to clinical trials, but microbial therapies may offer a promising new treatment opportunity for patients suffering from IBD.
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TABLE 3. Risk of Bias Summary of Studies
"+" indicates study meets criteria. "?" indicates unclear if study meets criteria.
